Anika Therapeutics, Inc.
ANIKNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ANIK. That does not mean none is planned.
Get an email about ANIK's next catalysts
Track Anika Therapeutics (ANIK) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
ANIK Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $0.02 | FQ end Sep/2026 | Call: bmo
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cingal | Phase 3 | Osteoarthritis, Knee | - | - |
Triamcinolone Hexacetonide | Phase 3 | Knee Osteoarthritis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Anika Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Anika Therapeutics, Inc.'s (ANIK) pipeline across Phase 3. Its lead program is Cingal (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Anika Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Anika Therapeutics, Inc. (ANIK) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ANIK biotech catalysts?→
Add ANIK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Anika Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.